Angiotensin II (ANG II) is a typical facilitatory stimulus for sodium appetite. Surprisingly, hyperosmolarity and central cholinergic stimulation, two classical antinatriorexigenic stimuli, also facilitate NaCl intake when they are combined with injections of the α 2 -adrenoceptor/imidazoline agonist moxonidine into the lateral parabrachial nucleus (LPBN). In the present study, we tested the relative importance of central angiotensinergic and cholinergic mechanisms for the control of water and NaCl intake by combining different dipsogenic or natriorexigenic stimuli with moxonidine injection into the LPBN. Adult male Holtzman rats (n = 9-10/group) with stainless steel cannulas implanted in the lateral ventricle and LPBN were used. Bilateral injections of moxonidine (0.5 nmol) into the LPBN increased water and 0.3 M NaCl intake in rats that received furosemide + captopril injected subcutaneously, ANG II (50 ng) or carbachol (cholinergic agonist, 4 nmol) injected intracerebroventricularly (icv) or 2 M NaCl infused intragastrically (2 ml/rat). Losartan (AT 1 antagonist, 100 μg) or atropine (muscarinic antagonist, 20 nmol) injected icv abolished the effects on water and 0.3 M NaCl of moxonidine combined to either 2 M NaCl intragastrically or carbachol icv. However, atropine icv did not change 0.3 M NaCl intake produced by direct central action of ANG II like that induced by ANG II icv or furosemide + captopril combined with moxonidine into the LPBN. The results suggest that different stimuli, including hyperosmolarity and central cholinergic stimulation, share central angiotensinergic activation as a common mechanism to facilitate sodium intake, particularly when they are combined with deactivation of the LPBN inhibitory mechanisms.
Introduction
Forebrain and hindbrain areas interconnect forming a circuitry that integrates facilitatory and inhibitory mechanisms to control sodium and water intake [1] [2] [3] [4] . The facilitation is counterbalanced by inhibitory mechanisms activated by signals that arise from visceral receptors, such as baroreceptors, taste receptors or osmoreceptors [1, [3] [4] [5] .
Tradition in the field has established that some models of dehydration may result in the expression of both water and sodium intake, whereas other models of dehydration induce thirst and inhibit of sodium intake. For example, during extracellular dehydration or hypovolemia, central angiotensinergic mechanisms are activated, and angiotensin II (ANG II) is a facilitatory signal to both water and sodium intake [1] [2] [3] [4] [5] [6] [7] . However, intracellular dehydration or hyperosmolarity, which activates osmoreceptors or brain acetylcholine are facilitatory to water intake, but have the potential to inhibit sodium intake [8] [9] [10] [11] [12] [13] [14] [15] [16] .
Previous studies have indicated that ANG II and acetylcholine may interact to control bodily-fluid balance. For example, the antagonism of ANG II AT 1 receptors inhibits thirst induced by brain cholinergic activation [17] . The same kind of antagonism also inhibits hypertension, vasopressin secretion and natriuresis induced by either brain cholinergic activation or hyperosmolarity [18] [19] [20] [21] [22] [23] [24] [25] . Therefore, activation of angiotensinergic mechanisms seems to be important for some of the responses induced by cholinergic activation. In this case, the two distinct mechanisms interact to produce similar behavior or a physiological response.
It is more difficult to understand and admit the interaction when the mechanisms are suggested to produce opposite effects in the same behavioral response. As mentioned above, ANG II is facilitatory to sodium intake and brain cholinergic activation may inhibit sodium intake, which might indicate that no interaction exists between these two mechanisms for the expression of this behavior. However, the blockade of the inhibitory mechanisms with injections of methysergide into the lateral parabrachial nucleus (LPBN) combined with central cholinergic activation induces NaCl intake, which suggests that this stimulus classically considered antinatriorexigenic also causes a facilitation of sodium intake [26] . In addition, recently it has been shown that forebrain activation of either ANG II or cholinergic receptors facilitates sodium intake in rats treated with GABA agonist injection into the LPBN, suggesting that sodium intake in this condition seems to depend on the activation of angiotensinergic and cholinergic receptors [27] [28] [29] . Therefore, the possibility that ANG II and brain cholinergic activation also interact to facilitate sodium intake in dehydrated rats needs to be addressed.
Several neurotransmitters modulate the activity of LPBN inhibitory mechanisms involved in the control of sodium intake in a dehydrated rat [28, [30] [31] [32] [33] [34] . For example, the activation of the α 2 -adrenoceptors with injections of moxonidine into the LPBN blocks the inhibitory mechanisms and, thereby, potentiate the typical 0.3 M NaCl intake induced by hypovolemia or ANG II [35] [36] [37] . Surprisingly, similar injections into the LPBN combined with hyperosmolarity elicit a paradoxical and substantial 0.3 M NaCl intake, which reinforces the idea that a stimulus classically considered antinatriorexigenic may also facilitate sodium intake [38, 39] .
In the present study, we investigated whether central angiotensinergic and cholinergic mechanisms interact to produce sodium intake in two different models of dehydration: hypovolemia and hyperosmolarity combined with moxonidine injections into the LPBN. The hypovolemia model was produced by combining a subcutaneous (sc) injection of diuretic furosemide (FURO) with angiotensin converting enzyme inhibitor captopril (CAP). This treatment produces a quick sodium appetite as a result of hypovolemia and mild hypotension associated to rapid increase in brain formation of ANG II [40, 41] . It was tested whether the cholinergic antagonist atropine injected intracerebroventricularly (icv) reduced sodium intake induced by combining FURO + CAP sc with moxonidine injected into the LPBN. In order to double check the effect of atropine in a model involving the angiotensinergic mechanism, it was also investigated whether this antagonist reduced sodium intake produced by combined injections of moxonidine into the LPBN and ANG II icv. In the hyperosmolarity model, rats received an intragastric (ig) load of 2 M NaCl combined with moxonidine into the LPBN to produce the paradoxical sodium intake [38] . The ANG II AT 1 receptor antagonist losartan or atropine was injected icv in hyperosmotic rats treated with moxonidine into the LPBN. In addition, it was also investigated whether the antagonists reduced sodium intake produced by combined injection of moxonidine into the LPBN and carbachol, a cholinergic agonist, icv.
Experimental procedures

Animals
A total of 52 male Holtzman rats weighing 290-310 g were used. Animals were housed in individual stainless steel cages with free access to normal sodium diet (BioBase Rat Chow, Águas Frias, Brazil), water and 0.3 M NaCl solution. Room temperature was maintained at 23 ± 2°C, humidity at 55 ± 10%, and on a 12:12 light-dark cycle. Rats had at least 5 days of free access to 0.3 M NaCl solution before tests. All experimental procedures were approved by Ethical Committee in Animal Use (CEUA) from School of Dentistry -UNESP (Proc. CEUA # 01/2011). Experimental protocols followed U.S. National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH publication no. 80-23, 1996).
Brain surgery
Rats were anesthetized with ketamine (80 mg/kg body wt; Cristália, Itapira, Brazil) combined with xylazine (7 mg/kg body wt; Agener União, Embu-Guaçu, Brazil) intraperitoneally, placed in a stereotaxic instrument (Kopf, Tujunga, USA) with the skull leveled between bregma and lambda. Two stainless steel 23-gauge guide cannulas were implanted bilaterally immediately above the LPBN (coordinates: 9.6 mm caudal to bregma, 2.1 mm lateral to midline, and 3.1 mm below dura mater) and a third cannula was implanted immediately above the left lateral ventricular (LV; coordinates: 0.8 mm caudal to bregma, 1.6 mm lateral to midline, and 2.7 mm below the skull). The tips of the guide cannulas were positioned at a point 2 mm above the LPBN and 1 mm above the LV. Dental acrylic resin and jeweler screws were used to fix the guide cannulas to the cranium. A 30-gauge metal obturator filled the guide cannulas between tests. Animals received an intramuscular injection of antibiotic (benzylpenicillin -80,000 IUs plus streptomycin -33 mg; Pentabiótico Veterinário -Pequeno Porte, Fort Dodge Saúde Animal Ltda., Campinas, Brazil) and a sc injection of analgesic/anti-inflammatory (ketoprofen 1% -0.03 ml/rat; Ketoflex, Mundo Animal, São Paulo, Brazil) at the end of surgery. Before starting water and 0.3 M NaCl intake tests, rats were allowed to recover from surgery for 5 days.
Drugs
Moxonidine hydrochloride, α 2 -adrenoceptor/imidazoline agonist (Sigma-Aldrich, St Louis, MO, USA) was dissolved in a mix of propylene glycol and water 2:1 (vehicle) and administered into the LPBN at the dose of 0.5 nmol/0.2 μl. Atropine methyl bromide (20 nmol/1.0 μl; muscarinic cholinergic receptor antagonist), carbachol (4 nmol/1.0 μl; cholinergic receptor agonist), losartan potassium (100 μg/1.0 μl; AT 1 receptor antagonist), and angiotensin II human (50 ng/1.0 μl) were purchased from Sigma-Aldrich and administered into the LV dissolved in saline.
Furosemide (Sigma-Aldrich) was dissolved in alkaline saline (pH adjusted to 9.0 with NaOH) and administered sc at 10 mg/kg body wt. Captopril (Sigma-Aldrich), angiotensin converting enzyme inhibitor, was dissolved in saline and administered sc at 5 mg/kg body wt.
Central injections
Hamilton syringes (5 μl; Hamilton, Reno, USA) connected by polyethylene tubing (PE-10; Clay Adams, Parsippany, USA) to a 30-gauge injection cannula were used for injections into LPBN and LV. At the time of testing, rats were removed from the cages, metal obturators were removed and the injection cannula (2 mm longer than the guide cannula) was inserted into the guide cannula. Injection volumes into the LPBN and LV were 0.2 μl each site and 1.0 μl, respectively. Metal obturators were replaced and the rats were returned to their cages after injections.
Water and 0.3 M NaCl intake tests
Tests in FURO + CAP-treated rats
In a group of rats (n = 9), water and 0.3 M NaCl intake was induced by sc injections of FURO (10 mg/kg body wt) + CAP (5 mg/kg body wt). Immediately after treatment with FURO + CAP, atropine (20 nmol/1.0 μl) or saline was injected into the LV. Rats were maintained without water and 0.3 M NaCl for 1 h. After this period, water and 0.3 M NaCl were offered to the animals and cumulative intake was recorded at 15, 30, 60, 90 and 120 min. Vehicle or moxonidine (0.5 nmol/0.2 μl) was injected into the LPBN 15 min before access to water and 0.3 M NaCl. Sequence of treatments into the LV and LPBN was randomized and each rat received all three combinations of treatments: (1) saline into the LV + vehicle into the LPBN; (2) saline into the LV + moxonidine into the LPBN; (3) atropine into the LV + moxonidine into the LPBN. A recovery period of at least 2 days was allowed between tests. During the tests rats had no access to food.
Tests in fluid-replete rats
Rats (n = 9) were tested in their home cages with no access to food during the test. Water and 0.3 M NaCl were provided from burettes with 0.1 ml divisions that were fitted with metal drinking spouts. Animals received injections of atropine (20 nmol/1.0 μl) or saline into the LV and moxonidine (0.5 nmol/0.2 μl) or vehicle into the LPBN. Fifteen minutes later, ANG II (50 ng/1.0 μl) was injected into the LV. Cumulative water and 0.3 M NaCl intake was recorded at 15, 30, 60, 90 and 120 min starting immediately after ANG II injection. The sequence of treatments into the LV and LPBN was randomized and each rat received all three combinations of treatments: (1) saline + ANG II into the LV + vehicle into the LPBN; (2) saline + ANG II into the LV + moxonidine into the LPBN; (3) atropine + ANG II into the LV + moxonidine into the LPBN.
Another group of animals (n = 15) received injections of atropine (20 nmol/1.0 μl), losartan (100 μg/1.0 μl) or saline into the LV and moxonidine (0.5 nmol/0.2 μl) or vehicle into the LPBN. Fifteen minutes later, carbachol (4 nmol/1.0 μl) was injected into the LV. Cumulative water and 0.3 M NaCl intake was recorded at 15, 30, 60, 90 and 120 min starting immediately after carbachol injection. The sequence of treatments into the LV and LPBN was randomized and each rat received all four combinations of treatments: (1) saline + carbachol into the LV + vehicle into the LPBN; (2) saline + carbachol into the LV + moxonidine into the LPBN; (3) atropine + carbachol into the LV + moxonidine into the LPBN; (4) losartan + carbachol into the LV + moxonidine into the LPBN.
A recovery period of at least 2 days was allowed between tests.
Tests in hyperosmotic rats
Water, 0.3 M NaCl and food were removed from the cage and animals (n = 19) received an ig load of 2 M NaCl (2 ml/rat) followed by an icv injection of atropine (20 nmol/1.0 μl), losartan (100 μg/1.0 μl) or saline. Forty-five minutes after ig load, moxonidine (0.5 nmol/0.2 μl) or vehicle was injected bilaterally into the LPBN. Fifteen minutes after moxonidine, animals had access to water and 0.3 M NaCl and cumulative intake was recorded at 15, 30, 60, 90 and 120 min. The sequence of treatments into the LV and LPBN was randomized and each hyperosmotic rat received all four combinations of treatments: (1) saline into the LV + vehicle into the LPBN; (2) saline into the LV + moxonidine into the LPBN; (3) atropine into the LV + moxonidine into the LPBN; (4) losartan into the LV + moxonidine into the LPBN. A recovery period of at least 2 days was allowed between tests.
Histology
At the end of the last intake test, rats received injections of 2% Evans Blue solution into each site in the same volume used for drug injections. They were then deeply anesthetized with sodium thiopental (80 mg/kg of b. wt.; Cristália) and perfused transcardially with saline followed by 10% formalin. Brains were removed, fixed in 10% formalin, frozen, cut in 50 μm sections, stained with Giemsa stain, and analyzed by light microscopy to confirm injection sites into the LPBN and LV.
Statistical analysis
Results are reported as means ± SEM. Two-way analysis of variance (ANOVA) using treatments and times as factors followed by Student-Newman-Keuls tests was used for comparisons. Differences were considered significant at P < 0.05. Fig. 1 shows the typical injection sites into the LPBN. The center of the LPBN injections was located in central and dorsal portions of the LPBN [see [42] for definitions of LPBN subnuclei]. The sites of the injection into the LPBN in the present study were similar to those of previous studies that showed effects of moxonidine into the LPBN on NaCl and water intake [9, 32, 38, [43] [44] [45] . In 15 rats used in the study the histological analysis showed that the injections were not performed correctly into the LPBN. Data from these animals were not included in the analysis. (Fig. 2) . The pre-treatment with icv injection of atropine (20 nmol/1 μl) did not change FURO + CAP-induced 0.3 M NaCl intake (27.5 ± 3.8 ml/2 h), but reduced water intake (14.7 ± 2.2 ml/2 h) in rats treated with moxonidine injected into the LPBN (Fig. 2). 3.3. Central ANG II-induced water and 0.3 M NaCl intake in rats treated with moxonidine into the LPBN combined with atropine icv
Results
Histological analysis
In rats that received injections of vehicle into the LPBN, the icv injection of ANG II (50 ng/1 μl) induced water intake (14.3 ± 1.5 ml/ 2 h) and only a small ingestion of 0.3 M NaCl (3.3 ± 1.0 ml/2 h) (Fig. 3) . Bilateral injections of moxonidine (0.5 nmol/0.2 μl) into the LPBN strongly increased icv ANG II-induced water (25.2 ± 2.5 ml/ 2 h) [F(2,16) = 6.50; P < 0.05] and 0.3 M NaCl intake (26.9 ± 2.7 ml/2 h) [F(2,16) = 26.81; P < 0.05] (Fig. 3) . The pretreatment with icv injection of atropine (20 nmol/1 μl) did not change ANG II-induced 0.3 M NaCl intake (23.6 ± 3.9 ml/2 h), but reduced water intake (18.8 ± 2.2 ml/2 h) in rats that received injections of moxonidine into the LPBN (Fig. 3) .
Water and 0.3 M NaCl intake by hyperosmotic rats treated with moxonidine into the LPBN combined with atropine or losartan icv
Bilateral injections of moxonidine (0.5 nmol/0.2 μl) into the LPBN in rats treated with ig 2 M NaCl significantly increased water (13.0 ± 4.4 ml/2 h, vs. vehicle into the LPBN: 6.9 ± 1.0 ml/2 h) [F (3,24) = 7.00; P < 0.05] and 0.3 M NaCl intake (18.6 ± 5.2 ml/2 h, vs. vehicle into the LPBN: 0.2 ± 0.1 ml/2 h) [F(3,24) = 10.96; P < 0.05] (Fig. 4) . The pre-treatment with icv injections of atropine (20 nmol/1 μl) or losartan (100 μg/1 μl) completely abolished water (0.7 ± 0.3 and 0.9 ± 0.8 ml/2 h, respectively) and 0.3 M NaCl intake (1.3 ± 0.4 and 0.6 ± 0.3 ml/2 h, respectively) induced by hyperosmolarity combined with moxonidine injected into the LPBN (Fig. 4) .
Water and 0.3 M NaCl intake in rats treated with moxonidine into the LPBN combined with carbachol + atropine or losartan icv
Carbachol (4 nmol/1 μl) injected icv in normohydrated rats that received injections of vehicle into the LPBN produced water intake 
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(5.0 ± 1.2 ml/2 h) and only a small 0.3 M NaCl intake (1.0 ± 0.2 ml/ 2 h). Bilateral injections of moxonidine (0.5 nmol/0.2 μl) into the LPBN significantly increased water (11.1 ± 3.6 ml/2 h) [F(3,27) = 7.98; P < 0.05] and 0.3 M NaCl intake (16.6 ± 5.8 ml/2 h) [F(3,27) = 6.12; P < 0.05] in rats treated with carbachol icv (Fig. 5) . The pretreatment with icv injections of atropine (20 nmol/1 μl) or losartan (100 μg/1 μl) abolished water (0.9 ± 0.6 and 1.2 ± 0.6 ml/2 h, respectively) and 0.3 M NaCl intake (2.4 ± 1.3 and 4.0 ± 2.0 ml/2 h, respectively) in rats treated with carbachol icv combined with moxonidine into the LPBN (Fig. 5 ).
Discussion
The present results suggest the participation of ANG II on 0.3 M NaCl intake elicited by hyperosmolarity or brain injection of the cholinergic agonist carbachol combined with moxonidine injected into the LPBN. These results together with previous studies showing the importance of ANG II for sodium intake induced by hypovolemia combined or not with LPBN blockade [1, [3] [4] [5] [6] [7] 35, 36, 39, 40, 45, 46] suggest ANG II as a common facilitatory mechanism to produce sodium intake when hypovolemia or hyperosmolarity was combined with the blockade of the LPBN inhibitory mechanism. In addition, similar to brain angiotensinergic mechanisms, the central cholinergic receptors are also important for water and NaCl intake in hyperosmotic rats, suggesting an interaction between these mechanisms in the pathway activated by osmoreceptors to facilitate NaCl intake. However, brain cholinergic receptor activation is not necessary for NaCl intake induced by hypovolemia or brain ANG II combined with LPBN inhibition. Previous studies showed increases in sodium intake combining FURO + CAP or ig 2 M NaCl with moxonidine into the LPBN [32, 36, 38, 39] . These effects of moxonidine injected into the LPBN are suggested to depend on the blockade of gustatory signals that inhibit 
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Behavioural Brain Research 333 (2017) [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] sodium intake [44] . The present results extend those of previous studies showing that injections of moxonidine into the LPBN also increase water and 0.3 M NaCl intake in rats treated with central ANG II or carbachol, which reinforces the suggestion that α 2 adrenergic activation in the LPBN is an important modulator of LPBN inhibitory mechanism. In spite of the strong increase of sodium intake when combined with different dipsogenic or natriorexigenic stimuli, injections of moxonidine alone into the LPBN without any additional treatment produce no change on sodium intake. This demonstrates that moxonidine injected into the LPBN has per se no facilitatory action on sodium intake [32] . The increased plasma osmolarity due to ingestion of hypertonic NaCl may stimulate ingestion of water when water and 0.3 M NaCl are simultaneously available (two bottle test). Thus, reduced ingestion of water after central angiotensinergic or cholinergic blockade in rats treated with moxonidine into the LPBN in some cases might be a consequence of reduced ingestion of hypertonic NaCl. However, reduction in water intake also occurred without significant changes in NaCl intake when atropine was injected icv in rats treated with FURO + CAP sc or ANG II icv. This reduction confirms previous suggestions that water intake depends also on the activation of central cholinergic mechanisms in addition to central angiotensinergic mechanisms [20, 47, 48] .
ANG II is a peptide clearly involved in the control of water intake and NaCl intake [1, 46] . The activation of central angiotensinergic mechanisms induces a gradual and slow developing NaCl intake [1, 49] . However, after the blockade of the LPBN with moxonidine or the serotonergic agonist methysergide, ANG II icv causes an immediate and intense 0.3 M NaCl intake [36] . Methysergide, like moxonidine, injected into the LPBN also significantly increases 0.3 M NaCl intake in rats treated with FURO + CAP [32, 36, 40, 41] . In addition to ANG II, hyperosmolarity and central cholinergic stimulation, classically known as dipsogenic and anti-natriorexigenic stimuli, may also produce facilitatory signals for sodium intake in addition to the usual inhibitory signals [9, 26, 27, 29, 38, 39] . An increase in plasma osmolarity produced by an ig load of 2 M NaCl facilitates 0.3 M NaCl intake in addition to the usual water intake provided that LPBN inhibitory mechanisms are blocked by bilateral injections of methysergide or moxonidine [38, 39] . This suggests that hyperosmolarity also activates mechanisms that facilitate sodium appetite, nevertheless, concurrent activation of LPBN inhibitory mechanisms would counteract this facilitatory effect, restraining NaCl intake [39] . Carbachol icv, besides thirst, also facilitates NaCl intake when combined with LPBN injections of methysergide [26] or moxonidine (present study), which suggests that similar to hyperosmolarity, central cholinergic activation may also produce facilitatory signals for sodium intake in addition to the usual inhibitory signals.
The blockade of central AT 1 receptors abolishes sodium intake in rats treated with ANG II or FURO + CAP combined with the blockade of the LPBN mechanisms or not [37, 41, 50, 51] . However, as shown by the present results, the blockade of central cholinergic mechanisms with atropine did not modify sodium intake in rats treated with ANG II icv or FURO + CAP sc combined with moxonidine into the LPBN, suggesting that cholinergic mechanisms are not part of the pathway activated by ANG II to facilitate sodium intake. These results are similar to those of previous studies showing that cholinergic antagonists do not change or only partially reduce ANG II-induced pressor response and thirst [20, 47, 48] . On the other hand, losartan injected icv also abolished water and NaCl intake in rats that received carbachol icv combined with moxonidine into the LPBN, which suggests that central cholinergic stimulation depends on the activation of angiotensinergic mechanisms to facilitate water and NaCl intake. The present results also show that atropine or losartan injected icv abolished water and 0.3 M NaCl in rats treated with ig 2 M NaCl combined with moxonidine into the LPBN, which suggests that cholinergic and angiotensinergic mechanisms are activated by hyperosmolarity to facilitate sodium intake in this condition.
The importance of AT 1 receptors was previously demonstrated for hyperosmolarity-induced natriuresis, vasopressin secretion, pressor response and c-Fos expression in the median preoptic nucleus, paraventricular nucleus and supraoptic nucleus [21, 22, 24, 52] . The present results extend those of previous studies suggesting that hyperosmolarity also activates angiotensinergic mechanisms to facilitate sodium intake. Fig. 6 is a schematic model that illustrates the possible interaction between the facilitatory mechanism activated by hyperosmolarity in the forebrain and the LPBN inhibitory mechanisms for the control of sodium intake. Facilitatory and inhibitory signals involved in the control of sodium intake may reach an integrative area that perhaps is the central nucleus of the amygdala [43] . Osmoreceptors activate a pathway involving cholinergic and finally angiotensinergic mechanisms to release facilitatory signals for sodium intake in the integrative area. The LPBN receives signals from the nucleus of the solitary tract/area postrema that arise from peripheral baroreceptors and other systemic visceral receptors including osmoreceptors and taste receptors. These signals release different neurotransmitters, among them noradrenaline acting on α 2 adrenoceptor or serotonin that modulate the activity of the LPBN. The facilitatory signals produced by hyperosmolarity are completely blocked by the activity of the LPBN inhibitory mechanisms and no sodium is ingested by hyperosmotic animals. Moxonidine deactivates the LPBN inhibitory mechanisms releasing the action of the facilitatory signals produced by osmoreceptor activation as the first step and ANG II release as the last and common step for different stimuli to facilitate sodium intake. At least cholinergic mechanisms are also part of the pathway activated by osmoreceptor to induce sodium intake, however, it is not possible to completely exclude the involvement of other neurotransmitters in this pathway.
Although the present results suggest an interaction between cholinergic and angiotensinergic mechanisms to facilitate sodium intake, previous studies about the interaction between cholinergic and angiotensinergic mechanisms have shown controversial results. The antagonism of AT 1 receptors abolished the pressor response and natriuresis to carbachol icv, while other studies suggested that the inhibition of angiotensinergic mechanisms did not change the responses to cholinergic stimulation [18, 19] . Particularly for sodium intake, according to the Fig. 6 . Schematic model showing possible mechanisms involved in the control of sodium intake in a condition of hyperosmolarity. An integrative area receives inhibitory signals from the LPBN and facilitatory signals produced by osmoreceptor activation that affect sodium intake. Different neurotransmitters, among them noradrenaline acting on α 2 adrenoceptor or serotonin modulate the inhibitory mechanisms in the LPBN. Osmoreceptors activate a pathway involving cholinergic and finally angiotensinergic mechanisms to release facilitatory signals for sodium intake. Sodium intake is stimulated in a condition of hyperosmolarity only if the inhibitory mechanisms are deactivated, like when moxonidine is injected into the LPBN. 5-HT, serotonin; LPBN, lateral parabrachial nucleus; CVO, circumventricular organs; ANG II, angiotensin II; ACh, acetylcholine; NTS/AP, nucleus of the solitary tract/area postrema.
Behavioural Brain Research 333 (2017) [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] classical concepts it was not expected interaction between cholinergic and angiotensinergic mechanisms. In the classical view, hyperosmolarity and central cholinergic mechanisms should oppose the action of angiotensinergic mechanisms in the control of sodium intake [14, 49, 53] . Contrary to these classical concepts, the present results are the first to suggest interactions between cholinergic and angiotensinergic mechanisms in the control of sodium intake with the central angiotensinergic mechanisms as the final common pathway to facilitate sodium intake as shown in Fig. 6 . Therefore, the activation of AT 1 receptors by ANG II is a necessary step to facilitate sodium intake if the initial stimulus is fluid depletion, hyperosmolarity or central cholinergic activation.
In conclusion, the present results show that central cholinergic and angiotensinergic mechanisms are activated by hyperosmolarity to facilitate sodium intake, a behavior clearly expressed by the ingestion of significant amount of sodium when the LPBN mechanisms are deactivated. The cholinergic mechanisms depend on angiotensinergic mechanisms to facilitate sodium. The results suggest that central angiotensinergic is the final common mechanism activated by different dipsogenic/natriorexigenic stimuli including hyperosmolarity and central cholinergic activation to facilitate sodium intake. This reinforces the importance of ANG II and LPBN mechanisms for the control of sodium intake and again suggests that to reduce inhibition is as important as to increase facilitatory signals to induce sodium intake.
